Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;96(6):e29767.
doi: 10.1002/jmv.29767.

Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center

Barut Dogan  1 , Yildirim Arslan Sema  2 , Kunay Bora  1 , Umman Veysel  3 , Dernek Benan  4 , Kıran Taşçı Ezgi  5 , Akkus Kayali Gozde  6 , Derya Demir  7 , Nazan Ozsan  7 , Mine Hekimgil  7 , Sahbudak Bal Zumrut  2 , Karakoyun Miray  1 , Cetin Funda  1 , Aydogdu Sema  1
Affiliations

Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center

Barut Dogan et al. J Med Virol. 2024 Jun.

Abstract

The most prevalent malignancy that complicates both adult and pediatric solid organ transplantation is post-transplant lymphoproliferative disorder (PTLD). This study aimed to analyze the clinical and pathological characteristics, treatments, and outcomes of Epstein-Barr virus (EBV) DNAemia and PTLD in pediatric liver transplant recipients. A retrospective chart review was performed on 112 patients less than 18 years of age who underwent isolated orthotopic liver transplantation (OLT) between 2010 and 2022 at Ege University Children's Hospital. Data gathered for 1-year post-OLT included age at OLT, EBV, immunoglobulin (Ig)M/IgG status of the donor and recipient, indication for OLT, induction regimen, all immunosuppression levels, date and result of EBV polymerase chain reaction testing, rejection episodes documented by liver biopsy, and the development of PTLD. Forty-nine patients (43.75%) developed EBV DNAemia (median interval from surgery: 2 months, min-max: 2-36), of which 43 (87.8%) grafts came from living donors, and 6 (12.2%) came from deceased donors. Nine (18.4%) patients died during follow-up, and eight (16.3%) developed PTLD. Of these 8 patients; five patients developed EBV-related disease, one child developed hemophagocytic lymphohistiocytosis, one developed aplastic anemia, and one child developed B cell lymphoma. When PTLD patients and without-PTLD patients were compared, pediatric intensive care unit hospitalization, abnormal bone marrow biopsy findings, lymphadenopathy, age at diagnosis of EBV DNAemia, EBV viral load, tacrolimus (FK 506) pre-infection, were higher and tacrolimus 1-month levels were lower in patients with PTLD (p < 0.05). In logistic regression analysis, we showed that the age at diagnosis of EBV DNAemia was significantly higher in children with PTLD (p = 0.045; OR: 1.389; 95% CI: 1.007-1.914). PTLD is a rare but severe complication associated with EBV after OLT. This study demonstrated that PTLD is associated with older age, higher tacrolimus blood levels before EBV DNAemia, and higher peak EBV viral load at 1 month of EBV DNAemia.

Keywords: Epstein‐Barr virus; pediatric liver transplantation; post‐transplant lymphoproliferative disorder.

PubMed Disclaimer

References

REFERENCES

    1. Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011;16(3):274‐280. doi:10.1097/MOT.0b013e3283465715
    1. Inayat F, Hassan GU, Tayyab GUN, Saif MW. Post‐transplantation lymphoproliferative disorder with gastrointestinal involvement. Ann Gastroenterol 2018;31(2):248‐251. doi:10.20524/aog.2018.0226
    1. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein‐Barr virus‐associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003;75(7):987‐993. doi:10.1097/01.TP.0000057244.03192.BD
    1. Cacciarelli T V., Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long‐term risk of post‐transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Tranplant 2001;5(5):359‐364. doi:10.1034/j.1399-3046.2001.00021.x
    1. Younes BS, McDiarmid S V, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. 2000;70(1):94‐99.

LinkOut - more resources